Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,916,345.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $517.51, for a total value of $4,916,345.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $167,902,496.93. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

United Therapeutics Stock Performance

United Therapeutics stock traded down $5.08 during trading hours on Monday, hitting $510.38. 536,220 shares of the stock were exchanged, compared to its average volume of 488,973. The stock has a market capitalization of $21.89 billion, a P/E ratio of 18.26, a P/E/G ratio of 1.75 and a beta of 0.59. The business’s 50-day moving average is $530.46 and its two-hundred day moving average is $539.16. United Therapeutics Corporation has a 12 month low of $303.08 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the business posted $6.41 earnings per share. On average, equities analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of several recent research reports. Bank of America dropped their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Royal Bank Of Canada reduced their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System raised its holdings in United Therapeutics by 55,526.2% during the second quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock worth $18,036,953,000 after acquiring an additional 33,229,108 shares in the last quarter. BlackRock Inc. bought a new position in United Therapeutics in the second quarter valued at approximately $2,868,735,000. Wellington Management Group LLP grew its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Jupiter Topco LLC bought a new position in United Therapeutics in the second quarter valued at approximately $450,140,000. Finally, Norges Bank acquired a new position in shares of United Therapeutics during the 4th quarter worth approximately $293,418,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.